[ET Net News Agency, 29 September 2022] BRII-B (02137) fell 6.47% to HK$5.35.
It hits an intra-day low of HK$5.35, hitting a historical low, and an intra-day high of
HK$5.84. The total shares traded was 405,500, with a value of HK$2.29m. The active
buy/sell ratio is 25:75, with net selling turnover of HK$1.08m. HSBC SEC BRO (ASIA)
accounts for greatest net responsive buying turnover of HK$359,902, with volume weighted
average price of HK$5.71. MORGAN STANLEY HK SEC accounts for greatest net responsive
selling turnover of HK$62,250, with volume weighted average price of HK$5.596. The stock
has fallen a combined 9.32% over the past 2 consecutive trading days.
The Hang Seng Index now rose 52 points, or 0.3% to 17,303; the Hang Seng China
Enterprises Index now fell 3 points, or 0.06% to 5,955; the Hang Seng TECH Index now fell
27 points, or 0.77% to 3,499; with an overall turnover of HK$50.77b.
The SSE Composite Index now fell less than 1 point to 3,044, with an overall turnover of
RMB205.01b.
The SZSE Component Index now rose 30 points, or 0.28% to 10,930, with an overall
turnover of RMB110.86b.
Basic Information
=================
----------------------------------
Nominal 5.350 % Chg -6.47%
High 5.840 Low 5.350
Shares Tr 405,500 Turnover 2.29m
10-D SMA 5.823 %H.V 76.859
20-D SMA 6.396 VWAP 5.656
50-D SMA 7.714 RSI14 30.843
----------------------------------
Status: Hitting a historical low, active buy/sell ratio is 25:75, with net selling
turnover of HK$1.08m, falling a combined 9.32% over the past 2 consecutive trading days
Performance of stocks in the same sector or of relevance
========================================================
Stock (Code) Price (HK$) Change (%)
-----------------------------------------------
BRII-B (02137) 5.35 -6.47
GENSCRIPT BIO (01548) 17.50 +3.92
INNOVENT BIO (01801) 25.30 +2.02
JXR (01951) 3.97 -5.92
WUXI BIO (02269) 48.05 -0.62
TIGERMED (03347) 64.25 +2.80
CANSINOBIO (06185) 46.00 +0.55
AKESO-B (09926) 22.40 +3.23
KINTOR PHARMA-B (09939) 11.08 -2.29
REMEGEN-B (09995) 37.60 -0.66
-----------------------------------------------
(ed)